GlassScriptPhysician profile
Jerrie Haney-Weaver
NPI 1528086097
$3,969.91
in general payments reported to CMS, 2019-2025
38 companies · $413 in 2025
The $413 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $123 · 2021: $603 · 2022: $994 · 2023: $926 · 2024: $659 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,997.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $668.23 | 2019-2023 | |
| Exeltis, USA INC. | $563.83 | 2020-2025 | Slynd |
| Aspira Women'S Health INC | $354.40 | 2022-2024 | Ova1 |
| Astellas Pharma US INC | $323.61 | 2020-2025 | Veozah |
| Mayne Pharma Commercial LLC | $299.37 | 2021-2025 | |
| Daiichi Sankyo INC. | $218.04 | 2020-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $166.73 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $147.78 | 2024-2025 | Zurzuvae |
| Organon LLC | $135.63 | 2021-2024 | Nexplanon |
| Medtronic, INC. | $131.56 | 2022-2024 | V-Loc 180 |
| Channel Medsystems, INC. | $126.87 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.51 | 2019-2025 | |
| Myovant Sciences INC. | $75.57 | 2022 | |
| Hologic Sales and Service, LLC | $69.17 | 2019-2021 | |
| Shield Therapeutics INC | $43.38 | 2023 | Accrufer |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $43.04 | 2019-2024 | Shockpulse |
| Agile Therapeutics, INC. | $42.77 | 2021-2022 | |
| Boston Scientific Corporation | $42.64 | 2023-2025 | Axonics, Advantage System |
| Smith+Nephew, INC. | $41.97 | 2025 | Pico |
| Pfizer INC. | $37.96 | 2023-2025 | |
| Mylan Pharmaceuticals INC. | $36.79 | 2019 | |
| Merck Sharp & Dohme LLC | $33.35 | 2019 | |
| Monaghan Medical Corporation | $29.83 | 2024 | Aeroeclipse |
| Axonics, INC. | $25.57 | 2024 | Axonics, Bulkamid |
| Northgate Technologies, INC. | $21.87 | 2024 | Stimsite |
| Roche Diagnostics Corporation | $21.62 | 2021 | |
| Coopersurgical, INC. | $19.66 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.10 | 2025 | Qelbree |
| Mycovia Pharmaceuticals, INC. | $19.03 | 2023 | Vivjoa |
| Avion Pharmaceuticals | $17.59 | 2019 | |
| Ethicon US, LLC | $16.16 | 2021 | |
| Millicent US INC | $15.92 | 2025 | Femlyv |
| Vertical Pharmaceuticals, LLC | $15.87 | 2020 | |
| Duchesnay USA Incorporated | $14.88 | 2019 | |
| Minerva Surgical, INC | $13.63 | 2023 | |
| Medtronic Vascular, INC. | $12.54 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $12.53 | 2019 | |
| Evofem Biosciences, INC. | $11.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerrie Haney-Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.